Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

Ozempic and other weight loss drugs have found their home in Kentucky, even though researchers from Washington University in ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a study ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...